Ralph Weichselbaum
Ralph R.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Ralph R. Weichselbaum (born 12 December 1945 in Chicago ) is an American physician specializing in radiation oncology, a member of the Institute of Medicine of the National Academy of Sciences, Ludwig professor, He is Daniel K. Ludwig Distinguished Service Professor of Radiation Oncology and Chairman, Department of Radiation and Cellular Oncology, at the University of Chicago Pritzker School of Medicine, and Head of the University of Chicago Center for Radiation Therapy, and the director of the Chicago Tumor Institute. Weichselbaum is also Co- Director of the Ludwig Center for Metastasis Research at the University of Chicago.
Career
Weichselbaum's research interests range from innovative multidisciplinary clinical programs in head and neck cancer treatments, to laboratory studies of repair signal transduction and DNA recombination, ionizing radiation, gene-targeted radiotherapy, chemoprevention, gene expression profiling in cancer, and angiogenic therapy. Much of this work was done in collaboration with Donald Kufe at The Harvard Medical School.
Most recently Weichselbaum in collaboration with Yang Xin Fu has identified a role for large dose radiotherapy in the stimulation of the immune system and a critical role for interferon expression in both host and tumor responses to radiotherapy. Weichselbaum was strongly influenced in his studies of virus and radiation and the interaction of radiation and interferon by Bernard Roizman.
He and Samuel Hellman were the first to propose the oligometastatic paradigm while advocating use of local control to prevent systemic spread and use as potentially curative treatment. The oligometastatic paradigm of cancer has been used by medical oncologists, surgical oncologists, interventional radiologists, and radiation oncologists to increase long-term survival with appropriately targeted therapy.
Dr. Weichselbaum was an early advocate of using utility curves to guide cancer treatment rather than focusing solely on five-year survival rates, and set up the first Department of Radiation and Cellular Oncology. He is a founding scientist of GenVec, creating an adenovector to carry a cytokine to targeted cells
Text derived from https://en.wikipedia.org/w/index.php?oldid=1233498749 under CC BY-SA 4.0; modifications have been made.
References
1 claim could not be tied to a specific sentence and is listed in the table below instead.